drugset
drugset / Trial / NCT01016327

Study of NMS-1116354 in Solid Tumors

NCT01016327 ↗

Phase 1 Terminated 15 enrolled Nerviano Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced solid tumors.

Timeline

Start
2009-04
Primary completion
2011-12
Completion
2012-09

Outcome

Outcome not reported

Stopped: “Discontinuation of clinical investigation with NMS-1116354”

Drugs

EvaluationDrugModalityDoseRoute
Subject NMS-1116354 Unknown — Oral

Indications

cancer